Review Papers Claim by Claim

Quarter 1 2025 AMSP Surveillance Brief

Australia reported 27 laboratory confirmed invasive meningococcal disease notifications from 1 January to 31 March 2025; serogroup B accounted for 18/25 (72%) of cases with serogroup known and antimicrobial testing recorded one penicillin resistant MenB isolate while all isolates remained susceptible to ceftriaxone, ciprofloxacin and rifampicin AMSP Q1 2025 Surveillance Report

Detailed critical review and analysis

Executive summary

The Australian Meningococcal Surveillance Programme (AMSP) quarterly report for 1 January to 31 March 2025 presents surveillance counts and limited laboratory antimicrobial resistance (AMR) data. Key reported points: 27 laboratory confirmed invasive meningococcal disease (IMD) notifications in Q1 2025; serogroup determined in 25/27 cases; MenB responsible for 18/25 (72%) of typed cases (down from 84% in Q1 2024) and one penicillin resistant MenB isolate detected while ceftriaxone, ciprofloxacin and rifampicin susceptibility were retained AMSP Q1 2025 Surveillance Report

What the report does well

• Timely national surveillance: provides near real-time quarterly counts of laboratory confirmed IMD and serogroup breakdown enabling trend detection across jurisdictions Quarterly surveillance counts and serogroup data
• Inclusion of AMR data (new in 2024): adds sentinel antibiotic susceptibility information for ceftriaxone, penicillin, ciprofloxacin and rifampicin that is critical for clinical guidance and prophylaxis policy AMR inclusion in quarterly reports

Main limitations and blind spots

1. Small absolute numbers limit inference: 27 notifications nationally (25 typed) is a small sample; proportional changes (eg MenB 72% vs 84% in 2024) are vulnerable to stochastic variation and reporting delays, so apparent shifts should be interpreted cautiously Small sample size in Q1 2025
2. Sentinel AMR but limited detail: AMR summary reports one penicillin resistant isolate among 14 culture diagnosed IMD cases (per Table 1) and states universal susceptibility to ceftriaxone, ciprofloxacin and rifampicin. The report lacks MIC distributions, testing methods (eg CLSI or EUCAST breakpoints), and raw isolate counts by jurisdiction which constrains assessment of emerging resistance trends and reproducibility of results Limited AMR methodological detail
3. Quarterly format limits depth: by design the AMSP quarterly brief restricts content to counts by jurisdiction and serogroup; important contextual data are missing from this brief, including age distribution, clinical outcomes, typing beyond serogroup (eg porA MLST or clonal complexes), vaccination status, and carriage data which are generally reported in annual reports but are essential for mechanistic inference and public health response planning Quarterly brief scope limitations
4. Possible underascertainment and reporting lag: surveillance depends on laboratory confirmation and reporting; PCR-only diagnoses and culture-negative cases may have incomplete typing or AMR data and could bias serogroup and AMR proportions if their distribution differs from culture positives Laboratory confirmation and reporting limitations

Data synthesis and simple reanalysis

Extracted numeric summary for Q1 2025 used for visualization and critique:

• Total notifications Q1 2025: 27
• Serogroup determined: 25/27
• MenB notifications: 18 (72% of those typed)
• Comparison points: Q1 2024 MenB 84%; Q1 2019 total notifications 37 (prepandemic)
• AMR summary: among culture diagnosed IMD (n=14 culture positives reported in table text), one penicillin resistant MenB isolate; all isolates susceptible to ceftriaxone ciprofloxacin and rifampicin Extracted numeric surveillance data Q1 2025

Visualization

Interpretation and biological/public health implications

1) Continued dominance of MenB: MenB remains the predominant serogroup in early 2025 similar to the 2023 annual pattern; persistent MenB dominance is epidemiologically important because MenB vaccines and population coverage policies vary across countries and age cohorts, affecting public health strategies MenB predominance noted in AMSP

2) AMR sentinel signal: detection of a single penicillin resistant MenB isolate is important but must be contextualised — most meningococcal treatment guidelines rely on third generation cephalosporins (eg ceftriaxone) to which isolates here remain susceptible, and rifampicin and ciprofloxacin susceptibility for chemoprophylaxis appears intact in this dataset; however absence of MIC distributions and small numbers limit assessment of trend emergence AMR sentinel result in Q1 2025

Critical recommendations for AMSP reporting and surveillance practice

1. Provide methodological detail on AMR testing in quarterly tables: list testing method (eg broth microdilution), breakpoints used (EUCAST/CLSI), and MIC distributions for key antibiotics to improve interpretability and reproducibility.
2. Report age strata and vaccination status in quarterly briefs or an accompanying data table to enable more actionable public health interpretation (eg detect shifts in age-specific incidence or vaccine failures).
3. Include minimal molecular typing metadata for culture isolates in quarterly appendices (eg MLST clonal complex or porA type) to allow rapid recognition of concerning clones or capsular switching events that could herald outbreaks.
4. Publish raw deidentified line data or machine readable CSV for the quarter to facilitate independent analysis, meta-analyses, and reproducibility.
5. Flag uncertainty due to small numbers explicitly and use confidence intervals or Bayesian credible intervals for proportions to avoid overinterpretation of short-term fluctuations.

Counterpoints and limitations of this review

This critique relies solely on the published quarterly brief text and extracted table descriptions; the authors note the AMSP annual report contains fuller analyses including fine typing sequencing data and age/vaccination details that are beyond the scope of the quarterly summary. Hence some of the suggestions (eg publish MLST) may already be implemented in annual reporting. Also, surveillance systems necessarily trade off timeliness and depth; the quarterly brief appears designed for rapid situational awareness rather than exhaustive analysis Quarterly vs annual reporting role

What data would change the conclusions

• Additional culture confirmations with AMR profiling showing clustering of penicillin or cephalosporin reduced susceptibility would indicate an emerging resistance problem requiring clinical guideline review.
• Detection of a hypervirulent MenB clone (eg evidence of a clonal complex linked to outbreaks) in molecular typing would shift public health response from monitoring to active control measures.
• Vaccination records showing breakthrough cases after complete 4CMenB schedules in a specific age cohort would require vaccine effectiveness investigation.

Concluding assessment

The AMSP Q1 2025 quarterly report provides useful, timely surveillance signals: MenB remains predominant and AMR monitoring has been usefully incorporated. However, the small case counts and limited AMR/molecular detail in the quarterly brief constrain deeper epidemiological or clinical inference. Quarterly briefs serve situational awareness well but should be explicitly linked to machine-readable supplemental data and clear AMR methodology to maximize utility and reproducibility.

Author review links